Company Profile
Pfizer, Inc. Stock Price, News & Catalysts
- Ticker:
- PFE
- Exchange:
- NYSE
- Sector:
- Biopharma, Oncology, Vaccines
- Location:
- United States
Stock performance
27.50 USD (+0.33%)
Close
Last updated: October 6, 2026
146B USD
Market cap
Why the stock is moving
As of Oct 6, 2026, PFE closed up 0.33% at $27.50. No new same-company headline was identified in the current news window.
Company overview
Global Biopharmaceutical Company
Pfizer develops and commercializes medicines and vaccines across oncology, internal medicine, vaccines, and inflammation and immunology. Its portfolio combines internally discovered products with businesses and technologies acquired through transactions including Seagen, Biohaven, Arena Pharmaceuticals, and Global Blood Therapeutics.
Oncology and Antibody-Drug Conjugates
Pfizer's oncology portfolio includes Ibrance, Xtandi, Lorbrena, Braftovi, Talzenna, Padcev, Adcetris, Tivdak, and Elrexfio. The Seagen acquisition added a leading antibody-drug conjugate platform and commercial products, supporting development across breast, bladder, lung, hematologic, and other cancers through targeted agents and combination regimens.
Internal Medicine and Rare Disease
The internal-medicine business includes Eliquis in anticoagulation, Vyndaqel-family products in transthyretin amyloid cardiomyopathy, and medicines for cardiovascular, metabolic, and rare diseases. Pfizer also markets Hympavzi for hemophilia and is advancing additional programs in obesity, cardiometabolic disease, and genetically defined conditions.
Vaccines and Infectious Disease
Pfizer has a broad vaccine portfolio led by the Prevnar pneumococcal franchise, Abrysvo for respiratory syncytial virus, and Comirnaty for COVID-19. Research programs include higher-valency pneumococcal conjugate vaccines and next-generation vaccines intended to expand serotype coverage across pediatric and adult populations.
Inflammation and Immunology
The inflammation and immunology portfolio includes Xeljanz, Litfulo, Velsipity, and Cibinqo across rheumatologic, dermatologic, and gastrointestinal diseases. Pfizer is pursuing additional indications for these medicines, including nonsegmental vitiligo for Litfulo, while applying small-molecule and biologic approaches to immune-mediated conditions.
Obesity and Metabolic Pipeline
Pfizer is building an obesity portfolio around berobenatide, an injectable GLP-1 receptor agonist designed for monthly dosing, and additional internal and partnered candidates. The planned development program covers chronic weight management and obesity-related complications such as obstructive sleep apnea and knee osteoarthritis.
Future catalysts
- FDA PDUFA decision in the fourth quarter of 2026 on Talzenna plus Xtandi for HRR gene-altered metastatic castration-sensitive prostate cancer.
- Launch of a ten-study Phase 3 berobenatide development program during 2026 across chronic weight management and obesity-related comorbidities.
- Entry of Pfizer's fifth-generation 35-valent adult pneumococcal vaccine candidate into clinical development by the end of 2026, subject to regulatory alignment.
- Global regulatory filings for Litfulo in nonsegmental vitiligo based on positive Phase 3 TRANQUILLO and TRANQUILLO 2 results.
Recent news
- 01
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Pfizer, Inc. (PFE)?
Pfizer, Inc. (PFE) most recently closed at 27.50 USD, a +0.33% move versus the previous session.
What is the market cap of Pfizer, Inc. (PFE)?
Pfizer, Inc. currently has a market capitalization of 146B USD on BioPharmSignal.
What does Pfizer, Inc. do?
Global Biopharmaceutical Company Pfizer develops and commercializes medicines and vaccines across oncology, internal medicine, vaccines, and inflammation and immunology. Its portfolio combines internally discovered products with businesses and technologies acquired through transactions including Seagen, Biohaven, Arena Pharmaceuticals, and Global Blood...
On which exchange is PFE stock listed?
Pfizer, Inc. (PFE) is associated with NYSE, United States, Biopharma, Oncology, Vaccines.
What is COVID-19?
Vaccines and Infectious Disease Pfizer has a broad vaccine portfolio led by the Prevnar pneumococcal franchise, Abrysvo for respiratory syncytial virus, and Comirnaty for COVID-19.
Which conditions is Pfizer, Inc. targeting with COVID-19?
Pfizer, Inc. is associated with oncology, cancer therapeutics, immunology based on its company overview and current catalyst commentary.
How does Pfizer, Inc. describe recent progress with COVID-19?
FDA PDUFA decision in the fourth quarter of 2026 on Talzenna plus Xtandi for HRR gene-altered metastatic castration-sensitive prostate cancer. Launch of a ten-study Phase 3 berobenatide development program during 2026 across chronic weight management and obesity-related comorbidities. Entry of Pfizer's fifth-generation 35-valent adult pneumococcal vaccine...
What is GLP-1?
Obesity and Metabolic Pipeline Pfizer is building an obesity portfolio around berobenatide, an injectable GLP-1 receptor agonist designed for monthly dosing, and additional internal and partnered candidates.